New drug cocktail shows promise for rare eye cancer that spreads to liver
NCT ID NCT05542342
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, sitravatinib (a pill) and tislelizumab (an IV infusion), in 16 people with a rare eye cancer (uveal melanoma) that had spread to the liver. The goal was to see if the combo could shrink liver tumors better than current treatments. Participants received the drugs until their disease got worse or side effects became too severe. The study is now complete, and results will show how many patients had their tumors shrink.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA WITH LIVER METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital General Universitario de Valencia
Valencia, 46014, Spain
-
Hospital Universitario Virgen de la Macarena
Seville, Andalusia, 41009, Spain
-
Hospital Universitario la Paz
Madrid, 28046, Spain
-
Institut Catala Oncologia (ICO) L´Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain